- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
UK's Cancer Survival Progress Slows Amid Unequal Outcomes and Service Delays
Aug 26, 2025
Europe Small Molecule Drug Delivery Market: Industry Overview, Trends and Growth Opportunities Forecasted Till 2027
Aug 25, 2020
ADHD Therapeutics Market is expected to reach US$ 64,742.37 million by 2030
Jan 29, 2024
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020
Stomach Cancer Market is expected to reach US$ 10,751.42 million by 2030
Dec 28, 2023
Genentech’s Fenebrutinib Shows Breakthrough MS Results
Feb 16, 2026
Hospital Acquired Infection Treatment Market is expected to reach US$ 19,978.39 million by 2030
Dec 11, 2023